Skip to content

US · ACIU · BIOTECHNOLOGY

AC Immune S.A. (ACIU) intrinsic value and stock valuation

$1.95as of 2026-11-21 · Mkt cap 233.06M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

AC Immune S.A. DCF and intrinsic value

InvestorsCraft values ACIU with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ACIU’s statements →

AC Immune S.A. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Lausanne, VD 1015 acimmune.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$3.57M-25.4% 5y CAGRd
20132025
Net income
-$-70.45M
20132025
Free cash flow
-$-67.01M
20132025
Total equity
$44.9M-26.9% 5y CAGRd
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$3.57M$27.3M$14.8M$3.94M$0.00
Operating income-$-68.86M-$-52.38M-$-53.62M-$-70.85M-$-79.01M
Net income-$-70.45M-$-50.92M-$-54.23M-$-70.75M-$-73M
EPSd-$-699.26K-$-510.78K-$-640.34K-$-846.8K-$-973.98K
Operating cash flow-$-66.15M$65.8M-$-60.41M-$-73.57M-$-65.69M
Capital expenditure-$-860K-$-580K-$-800K-$-1.24M-$-2.63M
Free cash flow-$-67.01M$65.3M-$-61.21M-$-74.81M-$-68.32M
Total assets$154.4M$230.9M$182.8M$185.9M$261.4M
Total debt$4.55M$5.43M$3.5M$2.8M$2.91M
Net debt-$-22.28M-$-30.85M-$-75M-$-28.79M-$-79.31M
Total equity$44.9M$112.3M$160.6M$169M$232M
Cash and short-term investments$91.5M$165.5M$103.1M$122.6M$198.2M
Income statement
20252024202320222021
Revenue$3.57M$27.3M$14.8M$3.94M$0.00
Cost of revenue$0.00$62.6M$54.6M$0.00$0.00
Gross profit$3.57M-$-35.26M-$-39.8M$3.94M$0.00
Research and development expenses$56.4M$62.6M$54.6M$60.3M$62.3M
Selling, general and administrative expenses$11.7M$11.4M$10.6M$9.58M$10.9M
Other expenses$4.35M-$-56.89M-$-51.36M$4.86M$5.85M
Operating expenses$72.4M$17.1M$13.8M$74.8M$79M
Cost and expenses$72.4M$79.7M$68.4M$74.8M$79M
Interest income$1.86M$3.2M$1.04M$70K$6.49M
Interest expense$190K$130K$180K$350K$580K
Depreciation and amortization$2.5M$2.16M$2.21M$2.36M$2.41M
Ebitda-$-67.75M-$-48.62M-$-51.83M-$-68.03M-$-70.01M
Operating income-$-68.86M-$-52.38M-$-53.62M-$-70.85M-$-79.01M
Total other income/expenses, net-$-1.58M$1.47M-$-600K$110K$6.02M
Income before tax-$-70.45M-$-50.91M-$-54.22M-$-70.74M-$-72.99M
Income tax expense$0.00$0.00$10K$10K$0.00
Net income-$-70.45M-$-50.92M-$-54.23M-$-70.75M-$-73M
Weighted average shares outstanding$100.8M$99.7M$84.7M$83.6M$75M
Weighted average diluted shares outstanding$100.8M$99.7M$84.7M$83.6M$75M
Balance sheet
20252024202320222021
Cash and short-term investments$91.5M$165.5M$103.1M$122.6M$198.2M
Net receivables$680K$1.1M$15.1M$410K$970K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$96.8M$172M$125.2M$128.1M$202.6M
Property, plant and equipment, net$6.54M$8.09M$6.88M$7.07M$8.03M
Goodwill and intangible assets$50.5M$50.4M$50.4M$50.4M$50.4M
Long-term investments$580K$0.00$360K$0.00$0.00
Total non-current assets$57.6M$58.9M$57.7M$57.8M$58.8M
Total assets$154.4M$230.9M$182.8M$185.9M$261.4M
Accounts payable$2.07M$2.66M$1.68M$930K$2M
Short-term debt$850K$1.03M$670K$550K$570K
Deferred revenue$83.8M$0.00$140K$0.00$0.00
Total current liabilities$94.8M$100.8M$13.6M$11.5M$20M
Long-term debt$3.69M$4.4M$2.83M$2.25M$2.34M
Deferred revenue, non-current$2.34M$0.00$0.00$0.00$0.00
Total non-current liabilities$14.7M$17.8M$8.6M$5.47M$9.44M
Capital lease obligations$3.69M$5.43M$3.5M$2.8M$2.91M
Total liabilities$109.5M$118.6M$22.2M$17M$29.5M
Common stock$2.26M$2.23M$2.09M$1.8M$1.79M
Retained earnings-$-439.52M-$-368.24M-$-316.2M-$-264.01M-$-200.94M
Accumulated other comprehensive income (loss)$10K-$-10K-$-50K$10K$0.00
Total equity$44.9M$112.3M$160.6M$169M$232M
Total investments$65.3M$129.2M$24.9M$91M$116M
Total debt$4.55M$5.43M$3.5M$2.8M$2.91M
Net debt-$-22.28M-$-30.85M-$-75M-$-28.79M-$-79.31M
Cash flow statement
20252024202320222021
Net income-$-67.28M-$-50.92M-$-54.23M-$-70.75M-$-73M
Depreciation and amortization$2.39M$2.16M$2.21M$2.36M$2.41M
Stock-based compensation$0.00$5.47M$4.37M$3.33M$4.13M
Change in working capital-$-6.47M$107.5M-$-15.16M-$-8.43M$6.84M
Accounts receivable$880K$13.6M-$-14.8M$600K-$-100K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-570K$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-66.15M$65.8M-$-60.41M-$-73.57M-$-65.69M
Investments in property, plant and equipment-$-860K-$-580K-$-800K-$-1.24M-$-2.63M
Acquisitions, net$10K$0.00$0.00$0.00$0.00
Net cash used for investing activities$60.7M-$-105.29M$65.6M$23.8M-$-53.66M
Common stock issued$10K$110K$43.8M$10K$17.8M
Common stock repurchased$0.00$0.00$0.00-$-10K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-970K-$-1.12M$43.3M-$-1.35M$40.8M
Net change in cash-$-4.92M-$-42.22M$46.9M-$-50.63M-$-78.68M
Cash at end of period$26.8M$36.3M$78.5M$31.6M$82.2M
Operating cash flow-$-66.15M$65.8M-$-60.41M-$-73.57M-$-65.69M
Capital expenditure-$-860K-$-580K-$-800K-$-1.24M-$-2.63M
Free cash flow-$-67.01M$65.3M-$-61.21M-$-74.81M-$-68.32M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About AC Immune S.A.

        AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.

        CEO
        Martin Zügel
        Employees
        122
        Beta
        1.57

        Explore

        Frequently asked questions

        What is the intrinsic value of AC Immune S.A. (ACIU)?

        InvestorsCraft does not currently publish an intrinsic value for ACIU. How the IC value is calculated.

        Is ACIU undervalued?

        InvestorsCraft does not publish an undervaluation signal for ACIU at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.